Embedded Files
Published Date: 1/07/2024
A new AI protocol developed at UC San Diego can detect biomarkers in tumor biopsies, promising to cut weeks and thousands of dollars from cancer detection.
A new AI protocol developed at UC San Diego can detect biomarkers in tumor biopsies, promising to cut weeks and thousands of dollars from cancer detection.
A team of engineers and medical researchers at the University of California San Diego has developed a new artificial intelligence (AI) tool that can detect clinically actionable genomic alterations directly from tumor biopsy slides. The new AI protocol, called DeepHRD, has the potential to save weeks and thousands of dollars from clinical oncology treatment workflows for breast and ovarian cancers.
According to the researchers, the current genomic testing required to determine the best first-line cancer treatment specific for each individual patient is expensive and time-consuming, resulting in life-threatening delays in treatment. The new AI approach can provide accurate, instantaneous detection of cancer genomic biomarkers, allowing oncologists to prescribe treatment immediately after initial tissue diagnosis.
The researchers believe that this breakthrough AI technology will remove barriers of time and money, enabling immediate, universal access and equality to actionable genomic biomarker detection for people with advanced cancers, particularly in resource-constrained regions worldwide.
FAQS:
FAQS:
Q: What is the purpose of the DeepHRD AI protocol?
A: The DeepHRD AI protocol is designed to detect clinically actionable genomic alterations directly from tumor biopsy slides, allowing for rapid and low-cost detection of cancer biomarkers.
Q: How does the DeepHRD AI protocol work?
A: The DeepHRD AI protocol uses artificial intelligence to identify specific biomarkers for homologous recombination deficiency (HRD), a condition in which a cancerous cell loses a specific DNA damage repair mechanism.
Q: What are the benefits of the DeepHRD AI protocol?
A: The DeepHRD AI protocol has the potential to save weeks and thousands of dollars from clinical oncology treatment workflows for breast and ovarian cancers, and can provide accurate, instantaneous detection of cancer genomic biomarkers.
Q: Who can benefit from the DeepHRD AI protocol?
A: The DeepHRD AI protocol can benefit highly-informed, resourced populations, and can particularly help close the severe disparities gap in precision medicine, especially in resource-constrained, remote regions worldwide.
Q: What is the future of precision oncology with the DeepHRD AI protocol?
A: According to the researchers, this approach is the future of precision oncology, and can enable immediate, universal access and equality to actionable genomic biomarker detection for people with advanced cancers.
More Topics :
More Topics :
Page updated
Report abuse